Quick Answer
Elicio Therapeutics, Inc. reported Total Revenue of $2.30 million for fiscal year 2022.
Elicio Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2022 | $2.30M | -91.9% |
| 2021 | $28.31M | +883.1% |
| 2020 | $2.88M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $0.00 | -100.0% | — |
| September 30, 2022 | $0.00 | -100.0% | -100.0% |
| June 30, 2022 | $653.0K | +20.9% | -60.4% |
| March 31, 2022 | $1.65M | +344.2% | +12.9% |
| September 30, 2021 | $1.46M | +76.5% | +170.4% |
| June 30, 2021 | $540.0K | -25.9% | +45.6% |
| March 31, 2021 | $371.0K | -57.1% | -55.1% |
| September 30, 2020 | $827.0K | — | +13.4% |
- Elicio Therapeutics, Inc. showed a decrease of -91.9% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2022 period, Elicio Therapeutics, Inc.’s total revenue has declined by 20.1% (from $2.88 million to $2.30 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 17, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: